SCHEMBL4124388

SCHEMBL4124388

CS(=O)(=O)c1ccc(-c2cc(-c3ccc(F)cc3)nc(N3CCC(O)CC3)c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.45
MAPT P10636 2/20 0.45
ALDH1A1 P00352 2/20 0.45
LMNA P02545 2/20 0.45
MEN1 O00255 1/20 0.45
GLA P06280 1/20 0.45
POLB P06746 1/20 0.45
GAA P10253 1/20 0.45
KMT2A Q03164 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
GPR119 Q8TDV5 2/20 0.45
SCN9A Q15858 1/20 0.45
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
PTGS2 P35354 9/20 0.43
ESR1 P03372 1/20 0.42
ESR2 Q92731 1/20 0.42
CLK2 P49760 1/20 0.41
CLK3 P49761 1/20 0.41
DYRK1A Q13627 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4132988 0.89 KDM4E (0.54) KDM4EMAPTALDH1A1LMNAMEN1
SCHEMBL4000864 0.85 L3MBTL1 (0.47) KDM4EMAPTALDH1A1POLBL3MBTL1
SCHEMBL3996999 0.85 L3MBTL1 (0.47) KDM4EMAPTALDH1A1POLBL3MBTL1
SCHEMBL13621970 0.85 KDM4E (0.49) KDM4EMAPTALDH1A1LMNAMEN1
SCHEMBL4114066 0.83 GPR119 (0.44) LMNAMEN1KMT2AGPR119PTGS2
SCHEMBL13632704 0.79 SCN9A (0.48) KDM4EMAPTALDH1A1LMNAMEN1
SCHEMBL4358171 0.78 MAPT (0.45) KDM4EMAPTALDH1A1LMNAMEN1
SCHEMBL3452757 0.75 KDM4E (0.53) KDM4EMAPTALDH1A1LMNAMEN1
SCHEMBL3451064 0.74 PTGS2 (0.48) KDM4EMAPTALDH1A1LMNAMEN1
SCHEMBL3450958 0.74 CA12 (0.48) MAPTMEN1KMT2AMAPK1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060084644-A1 Novel pyridine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 US claimed
US-7622486-B2 Pyridine compounds, process for their preparation and compositions containing them REDDY US THERAPEUTICS, INC. (US) 2009-11-24 US disclosed
US-7622486-B2 Pyridine compounds, process for their preparation and compositions containing them REDDY US THERAPEUTICS, INC. (US) 2009-11-24 US disclosed
EP-1805142-A4 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS INC (US) 2009-06-10 EP disclosed
EP-1805142-A2 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM Reddy US Therapeutics, Inc. (US) 2007-07-11 EP disclosed
US-20060084644-A1 Novel pyridine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 US disclosed
WO-2006034474-A2 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS, INC. (US) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084644-A1 Novel pyridine compounds, process for their preparation and compositions containing them LDLR, LRP6, PLPBP KDM4E 1937/4885MAPT 4192/4885ALDH1A1 3749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.